Capacity Is a Price, Not a Number: Reading the UK Bulk Annuity Queue
Photo: USCG Press, CC BY 2.0, via Wikimedia Commons
For most of the past two decades, the UK defined benefit conversation was about deficit. It is now, for a great many schemes, about sequencing. Funding levels that have moved decisively into surplus have converted risk transfer from a discretionary endgame into a managed programme, and the practical question has shifted from whether to transact to when, and at what price, capacity will be available.
That shift has consequences for how trustees read the market. The queue is not a fixed number of places; it is a price mechanism, and the language of scarcity is doing work that the language of pricing should be doing.
The surplus that built the queue
Two forces have driven funding levels higher. The first is the sustained rise in long-dated gilt yields from 2022 onwards, which shrank liability valuations faster than it shrank assets for schemes with hedging in place. The second is the steady flow of sponsor contributions agreed under recovery plans that were struck when the outlook was considerably darker.
The result is that a large cohort of schemes now sits at or above the funding level at which a buy-in becomes affordable. Because scheme demographics are what they are, the decision has a deadline attached: every year of delay converts investment and longevity risk into an insurance premium that has to be paid eventually.
Capital is only the first gate
The bulk annuity market is often described as capacity-constrained, but capacity is a loose word covering at least four distinct constraints.
Regulatory capital. Insurers hold capital against longevity, credit and market risk under the matching adjustment regime. Reforms to that framework and to the wider Solvency UK architecture have been designed to release capital into productive assets, and part of that release has been directed towards annuity writing.
Asset supply. A buy-in is, in essence, a promise to hold long-dated, index-linked and fixed sterling cash flows for several decades. The supply of suitable assets — long gilts, investment-grade sterling credit, and increasingly private and infrastructure debt — determines how much liability an insurer can back efficiently. A shortage here shows up as price, not as a refusal.
Operational throughput. Each transaction requires data cleansing, asset transition, legal documentation and actuarial sign-off. Transaction teams are finite, and a scheme with imperfect records will find itself at the back of the queue regardless of how attractive its risk profile looks.
Reinsurance appetite. This is the constraint that has changed most in the past two years and deserves separate treatment.
Reinsurance: the second balance sheet
Funded reinsurance — where an offshore reinsurer takes on both the longevity risk and the asset risk, often posting collateral — has become a material component of UK bulk annuity economics. It allows insurers to write more volume against the same balance sheet, which is genuinely useful when demand is running at record levels.
It also introduces a dependency. Prudential scrutiny of these arrangements has tightened, with supervisors focused on counterparty concentration, collateral quality, recapture risk and the possibility that a correlated stress forces liabilities back onto the ceding insurer at an awkward moment. That is a sensible focus. The practical effect for schemes is that reinsurance capacity is not infinitely elastic: where a transaction relies heavily on funded arrangements, the pricing will reflect both the reinsurer's cost of capital and the insurer's own capital charge for the residual risk.
Trustees do not need to underwrite the reinsurance structure. They do need to understand whether a quotation depends on it, because a quote that cannot be executed is not a quote.
How pricing should respond
Where demand exceeds supply in a market with finite participants, prices adjust. The mechanisms are familiar.
- Widening of the pricing margin. Insurers quote a buffer above the theoretical best estimate. As the pipeline lengthens, that buffer tends to widen rather than narrow.
- Selectivity. Schemes with clean data, straightforward benefit structures and a single trustee board will be prioritised. Complexity gets priced, and sometimes gets deferred.
- Staged execution. More schemes are being offered partial buy-ins or tranched transfers, with the balance of risk retained or hedged. This spreads capacity further but leaves residual risk in the scheme.
- Premium on certainty. Insurers that can demonstrate a clean asset transition and a settled liability data set will charge less for the same risk. The discount here is real and often exceeds the cost of remedial data work.
None of this amounts to a prediction of a disorderly market. It does argue against the assumption that last quarter's pricing remains available this quarter simply because nothing in the scheme has changed.
What trustees should ask of a quotation
A buy-in quotation is a commercial offer with a defined validity window, and the questions that matter are the ones that determine whether it can be executed on the terms assumed.
- What is the quotation's expiry and what assumptions underpin the price? Longevity basis, expense loadings and asset mix should all be explicit.
- Does the price depend on a specific asset transition? If the insurer expects to receive particular gilts or credit at a specific yield, a change in market levels between quote and execution changes the outcome.
- How much of the transaction relies on reinsurance? Not for the detail, but for the execution risk.
- What is excluded? GMP equalisation, discretionary increases, and any benefits outside the data set are common gaps between quoted and final premium.
- What happens if the scheme's funding position improves further? Some structures allow for a premium adjustment; others do not, and the difference matters in a rising-surplus environment.
Execution is the part that is not priced
The most common source of disappointment in this market is not price. It is slippage between quotation and completion, driven by incomplete member data, unresolved benefit specifications, or an investment strategy that has not been de-risked ahead of the transaction.
The schemes that transact efficiently tend to be the ones that treated preparation as a project in its own right, months before approaching the market. In a queue, readiness is the only genuine advantage a scheme can manufacture for itself.